Blog

Latest news and articles!

Calgary, Alberta, January 26, 2023: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) (FSE:2VF0) is pleased to announce the Japan Patent Office  issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix

Calgary, Alberta, January 24, 2023: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) FSE:2VF0 is pleased to announce the Arbitrator has dismissed Dr. Burchardt’s claims  for compensation and damages against the Company,

Calgary, Alberta, January 23, 2023: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) FSE:2VF0 is pleased to announce it is hiring four new biotechnologists to re-establish the Company’s production of ACP-01 in

Calgary, Alberta, January 19, 2023: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) is pleased to announce it has received a $250,000 Letter of Commitment for funding from the McGill University Health

Calgary, Alberta, December 8, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTC:HMTXF; FSE:2VF0) is pleased to announce the Office of the Registrar of Trademarks, Republic of Cyprus,  issued Kwalata Trading Limited, a wholly

Calgary, Alberta, November 30, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTC:HMTXF; FSE:2VF0) thanks Mr. Niem Malo,  founder of Beefstro’s, for his ACP-01 testimonial interview now available on YouTube (https://youtu.be/1ezFC0oIU9s). Mr. Niem Malo

Calgary, Alberta, November 15, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTC:HMTXF; FSE:2VF0) is pleased to announce the continued evolution of its patented Automated Cell Therapy System (ACTS). The Hemostemix ACTS is designed

Calgary, Alberta, October 26, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV:HEM; OTC: HMTXF; FSE:2VFO) is pleased to announce Dr. Giannetti and Dr. Cecere as Co-Lead Medical Consultants, Cardiovascular Medicine and Clinical Trials. Dr.

Calgary, Alberta, October 25, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF) invites shareholders, brokers and financial advisors, institutional investors and analysts, to attend its real-time, interactive presentation at the Emerging

Calgary, Alberta, October 19, 2022: – Hemostemix Inc. (“Hemostemix” or the “Company”) (TSXV: HEM; OTC: HMTXF; FSE:2VFO) and its wholly-owned subsidiary, PreCerv Inc., are pleased to announce the commencement of PreCerv Inc.’s study of NCP-01.

Other news.